What’s the difference between Vyvanse and dextroamphetamine?
Vyvanse is a brand-name prescription medicine whose active ingredient is lisdexamfetamine (a prodrug). After you take it, your body converts it into dextroamphetamine. Dextroamphetamine is the active stimulant in many formulations, and it works directly as dextroamphetamine. Because of this, Vyvanse tends to have a smoother onset and longer duration compared with immediate-release dextroamphetamine products. [1][2]
How do they compare for onset and “how long it lasts”?
Vyvanse typically has a slower start and lasts longer because it needs conversion from lisdexamfetamine to dextroamphetamine in the body. Immediate-release dextroamphetamine acts sooner because it does not require that conversion step. Extended-release dextroamphetamine products (if prescribed) can also last longer, but their effect profile depends on the specific formulation. [1][2]
Are the effects and risks the same?
Both medications are amphetamine-based stimulants and share many of the same potential risks: appetite suppression, insomnia, increased heart rate and blood pressure, anxiety/irritability, and possible worsening of tics in some people. The smoother delivery of Vyvanse can change how noticeable side effects feel for some patients, but it does not remove the underlying stimulant-related risks. [1][2]
Which one is used for ADHD?
Both are used to treat ADHD in children and adults, but Vyvanse is specifically labeled for ADHD and is widely used when clinicians want a longer-acting option. Dextroamphetamine is also used for ADHD, including in formulations that can be immediate-release or extended-release depending on the product. [1][2]
What about binge eating (BED) or other off-label uses?
Vyvanse is approved for binge-eating disorder (BED) in adults in addition to ADHD. Dextroamphetamine is generally not the same labeled therapy for BED; prescribers sometimes use other stimulant strategies depending on the patient and local practice. [1][2]
What happens if you switch from one to the other?
Clinicians generally do not use “1:1” dose conversions solely by name, because Vyvanse is lisdexamfetamine (a prodrug) and dextroamphetamine formulations differ in release and timing. Switching typically involves choosing an equivalent regimen based on the patient’s prior response, side effects, and schedule needs. [1][2]
Do insurance or cost differences matter?
Brand-name Vyvanse is often more expensive than generic dextroamphetamine products, depending on coverage and the specific formulation available. Coverage can strongly influence which one a patient can start or continue, even when clinicians have a preference. [1][2]
Which should you choose?
Common decision factors are whether you need longer symptom coverage, how you respond to stimulant onset/“peaks,” and side effect tolerance. Vyvanse is often chosen for longer, smoother coverage, while dextroamphetamine (especially immediate-release) may be chosen for more immediate or flexible dosing—depending on the exact formulation prescribed. [1][2]
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206318
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016970